



CIHI Medication Reference Guide for interRAI Assessments

2026–2027



CIHI

Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

Unless otherwise indicated, this product uses data provided by provinces and territories in Canada.

All rights reserved.

The contents of this publication may be reproduced only in accordance with the terms of a valid and subsisting agreement with the Canadian Institute for Health Information.

For permission or information, please contact CIHI:

Canadian Institute for Health Information

350 Albert Street, Suite 1400

Ottawa, Ontario K1R 1A4

Phone: 613-241-7860

Fax: 613-241-8120

cihi.ca

copyright@cihi.ca

© 2026 Canadian Institute for Health Information

How to cite this document:

Canadian Institute for Health Information. *CIHI Medication Reference Guide for interRAI Assessments, 2026–2027*. Ottawa, ON: CIHI; 2026.

Cette publication est aussi disponible en français sous le titre *Guide de référence de l'ICIS sur les médicaments pour les évaluations interRAI, 2026-2027*.

CIHI Medication Reference Guide for interRAI Assessments, 2026–2027

The Canadian Institute for Health Information (CIHI) uses the Health Canada Drug Product Database to determine the medications that are included in the *CIHI Medication Reference Guide for interRAI Assessments*. Health Canada classifies these drugs using the World Health Organization’s Anatomical Therapeutic Chemical (ATC) classification system.

In the ATC classification system, the active substances are divided into different groups according to the organ or system on which they act and according to their therapeutic, pharmacological and chemical properties. Both the chemical name and examples of common product names are provided.

The ATC code can be used to determine the classification and appropriate coding of medications not included in this document. Drugs are classified in groups at 5 different levels: third-level ATC codes are provided for hypnotics, anti-anxieties, antidepressants and antipsychotics. All medications approved as such by Health Canada and with ATC classifications starting with these codes should be captured in their respective category. For example, a medication with an ATC code that begins with “N05A” would be captured as an antipsychotic/neuroleptic. The ATC code for a medication can be found by referring to Health Canada’s [Drug Product Database](#).

Some medications are included in a given category that is not the main ATC classification because they are used for the identified condition. An example is clonazepam, which is used to treat anxiety and is classified under Anti-anxieties as opposed to the main classification of Antiepileptics.

Classification	Chemical	Common product name
Antipsychotics/ neuroleptics (ATC classification: N05A)	Aripiprazole	Abilify
	Asenapine	Saphris
	Brexpiprazole	Rexulti
	Cariprazine	Vraylar
	Chlorpromazine	Chlorpromazine
	Clozapine	Clozaril
	Flupentixol	Fluanxol
	Fluphenazine	Fluphenazine
	Haloperidol	Haldol
	Levomepromazine (methotrimeprazine)	Nozinan, Methoprazine
	Lithium	Carbolith, Lithane
	Loxapine	Loxapac
	Lurasidone	Latuda
	Olanzapine	Zyprexa
	Paliperidone	Invega
	Periciazine	Neuleptil
	Perphenazine	Perphenazine
	Pimozide	Orap
	Prochlorperazine	Stemetil
	Quetiapine	Seroquel
Risperidone	Risperdal	
Ziprasidone	Zeldox	
Zuclopenthixol	Clopixol	

Classification	Chemical	Common product name
Antidepressants (ATC classification: N06A)	Amitriptyline	Elavil, Levate
	Bupropion	Wellbutrin
	Citalopram	Celexa
	Clomipramine	Anafranil
	Desipramine	Desipramine
	Desvenlafaxine	Pristiq
	Doxepin	Sinequan
	Duloxetine	Cymbalta
	Escitalopram	Ciprallex
	Esketamine	Spravato
	Fluoxetine	Prozac
	Fluvoxamine	Luvox
	Imipramine	Imipramine
	Levomilnacipran	Fetzima
	Mirtazapine	Remeron
	Moclobemide	Manerix
	Nortriptyline	Aventyl, Norventyl
	Paroxetine	Paxil
	Phenelzine	Nardil
	Sertraline	Zoloft
	Tranlycypromine	Parnate
	Trazodone	Trazodone
Trimipramine	Trimipramine	
Tryptophan	Tryptan	
Venlafaxine	Effexor	
Vilazodone	Viibryd	
Vortioxetine	Trintellix	

Classification	Chemical	Common product name
Anti-anxieties (ATC classification: A03C, N05B)	Alprazolam	Xanax
	Bromazepam	Bromazepam
	Buspirone	BuSpar
	Chlordiazepoxide	Chlordiazepoxide
	Clidinium–chlordiazepoxide combinations	Librax
	Clonazepam	Rivotril
	Clorazepate potassium	Clorazepate
	Diazepam	Valium
	Hydroxyzine	Atarax
	Lorazepam	Ativan
	Oxazepam	Oxpam
Hypnotics (ATC classification: N05C)	Chloral hydrate	Chloral hydrate syrup
	Daridorexant	Quviviq
	Dexmedetomidine	Precedex
	Doxepin	Silenor
	Eszopiclone	Lunesta
	Flurazepam	Flurazepam
	Lemborexant	Dayvigo
	Midazolam	Midazolam injection
	Nitrazepam	Mogadon
	Temazepam	Restoril
	Triazolam	Triazolam
	Zolpidem	Sublinox
Zopiclone	Imovane	

Appendix: Notes for 2026–2027

This appendix documents the changes to the *CIHI Medication Reference Guide for interRAI Assessments*.

Action taken	Chemical	Common product name
Added chemical	Bromazepam	Bromazepam
	Chlorpromazine	Chlorpromazine
	Chloral hydrate	Chloral hydrate syrup
	Clorazepate potassium	Clorazepate
	Desipramine	Desipramine
	Doxepin	Sinequan
	Doxepin	Silenor
	Fluphenazine	Fluphenazine
	Flurazepam	Flurazepam
	Imipramine	Imipramine
	Perphenazine	Perphenazine
	Triazolam	Triazolam
	Trazodone	Trazodone
	Trimipramine	Trimipramine
Removed chemical	Bromazepam	Lectopam
	Chloral hydrate	Noctec
	Chlorpromazine	Largactil
	Clorazepate potassium	Tranxene, Apo-Clorazepate
	Desipramine	Norpramin
	Diazepam	Diazemuls
	Doxepin	Doxepine
	Fluphenazine	Moditen
	Flurazepam	Dalmane, Somnol
	Imipramine	Tofranil
	Levomepromazine (methotrimeprazine)	Novo Meprazine
	Lithium	Duralith
	Perphenazine	Trilafon
	Thiopropazine	Majeptil
	Trazodone	Desyrel
	Triazolam	Halcion
	Trifluoperazine	Terfluzine
	Trimipramine	Surmontil
	Zopiclone	Rhovane

cihi.ca

82786-1125

